Jillian Douglas, DO
Endocrinology, Diabetes & Metabolism · Lewisburg, WVNPI 1851564256
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 193 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Novo Nordisk at 28.9% of the total.
Across 193 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$863
- Lilly USA, LLC$366
- Boehringer Ingelheim$313
- AstraZeneca$205
- Insulet Corporation$168
- Dexcom, Inc.$146
- plus $927 from 19 others
What the payments were for
- Food & beverage$2,988100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 70 | $863 |
| Lilly USA, LLC | 23 | $366 |
| Boehringer Ingelheim | 16 | $313 |
| AstraZeneca | 13 | $205 |
| Insulet Corporation | 10 | $168 |
| Dexcom, Inc. | 8 | $146 |
| AbbVie | 8 | $139 |
| Abbott | 7 | $127 |
| Bayer | 6 | $108 |
| Xeris Pharmaceuticals, Inc. | 5 | $81 |
| Johnson & Johnson | 5 | $78 |
| Tandem Diabetes Care, Inc. | 4 | $68 |
| Amgen | 4 | $67 |
| Cequr Corporation | 1 | $39 |
| Acella Pharmaceuticals, LLC | 2 | $30 |
| Merck | 2 | $25 |
| Medtronic | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Stryker | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $18 |
| EUSA Pharma (US) LLC | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Acclarent, Inc | 1 | $15 |
| Gilead | 1 | $13 |
How this compares
$2,988 in reported general payments places this provider in the 70th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 357 | $542,396 |
| TrulicityDulaglutide | 117 | $204,248 |
| OzempicSemaglutide | 114 | $198,493 |
| JardianceEmpagliflozin | 140 | $185,266 |
| Tresiba Flextouch U-200Insulin Degludec | 76 | $167,091 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 67 | $117,831 |
| FarxigaDapagliflozin Propanediol | 66 | $84,646 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 48 | $81,838 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $57,758 |
| JanuviaSitagliptin Phosphate | 35 | $50,542 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $46,691 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 65 | $32,308 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 132 | $27,868 |
| Novolog FlexpenInsulin Aspart | 64 | $25,283 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $24,476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $366 | $746,644474 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $863 | $233,691164 claims |
| Boehringer IngelheimJardiance | $313 | $185,266140 claims |
| AstraZenecaFarxiga | $205 | $84,64666 claims |
| MerckJanuvia, Janumet | $25 | $68,01647 claims |
| Johnson & JohnsonInvokana | $78 | $22,10713 claims |
| AbbVieSynthroid, Armour Thyroid | $139 | $21,696237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Lewisburg
- Daniel MaciasHuntington$686K
- Zachary KistkaMartinsburg$120K
- Jeremy SouleBridgeport$109K
- Philip RyanMartinsburg$35K
- John EplingBridgeport$28K
- Greta GuyerSouth Charleston$22K
- Arlene FederWeirton$20K
- Ziad KahwashSouth Charleston$17K
- Ayman ElkadryHuntington$13K
- Jessica PeriniMorgantown$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.